The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
1
wherein X, Y, Z, D and R
3
are as defined in the specification.
Also disclosed are compounds comprising
2
or a pharmaceutically acceptable salt or a prodrug thereof;
wherein A, X, J, and R
3
are as defined in the specification.
Also disclosed are compounds having an &agr; and an &ohgr; chain comprising
3
or derivatives thereof,
as defined in the specification
or pharmaceutically acceptable salts or prodrugs thereof.
Prostaglandin type compounds of the formula ##STR1## where X is CH.sub.2 --CH.sub.2, CH.dbd.CH cis or C.tbd.C; Y is CH.sub.2 or O; Z is H, OH, CH.sub.3 or CH.sub.2 OH and R is a linear, branched or cyclo alkyl chain of 3 to 7 carbon atoms, can be prepared by essentially a one-step reaction from a new intermediate of the formula ##STR2## where R represents a linear, branched or cyclo alkyl group of 3 to 7 carbon atoms; P is a removable protective group and z is H, OP,CH.sub.3 or CH.sub.2 OP. The intermediate is useful in making known and new PGEs useful as antihypertensives, gastric acid secretion inhibitors and smooth muscle stimulants.
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I;
wherein X, Y, Z, D and R
3
are as defined in the specification.